BEAM vs. RXRX

Last updated Jun 23, 2026

BEAM (Beam Therapeutics Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BEAM returned -16.23%/yr vs -37.56%/yr for RXRX. A 0.62 correlation means they provide meaningful diversification when combined.

Performance

BEAM vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Beam Therapeutics Inc. (BEAM) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BEAM achieves a 28.17% return, which is significantly higher than RXRX's -22.25% return.

BEAM

• 1D: 4.07%
• 1M: 24.06%
• YTD: 28.17%
• 6M: 27.26%
• 1Y: 111.99%
• 3Y*: 3.76%
• 5Y*: -16.23%
• 10Y*: —

RXRX

• 1D: -1.55%
• 1M: 5.65%
• YTD: -22.25%
• 6M: -27.73%
• 1Y: -36.78%
• 3Y*: -24.40%
• 5Y*: -37.56%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BEAM vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
BEAM Beam Therapeutics Inc.	28.17%	11.77%	-8.89%	-30.40%	-50.92%	8.01%
RXRX Recursion Pharmaceuticals, Inc.	-22.25%	-39.50%	-31.44%	27.89%	-54.99%	-42.90%

Correlation

The correlation between BEAM and RXRX is 0.56, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.56
Correlation (3Y) Calculated over the trailing 3-year period	0.61
Correlation (5Y) Calculated over the trailing 5-year period	0.63
Correlation (All Time) Calculated using the full available price history since Apr 16, 2021	0.62

The correlation between BEAM and RXRX has been stable across timeframes, ranging from 0.56 to 0.63 - a consistent structural relationship.

Fundamentals

Market Cap BEAM : $3.67B RXRX : $1.68B
EPS BEAM : -$0.63 RXRX : -$1.17
PS Ratio BEAM : 27.72 RXRX : 23.03
PB Ratio BEAM : 3.15 RXRX : 1.64
Total Revenue (TTM) BEAM : $132.27M RXRX : $66.29M
Gross Profit (TTM) BEAM : -$84.92M RXRX : -$22.83M
EBITDA (TTM) BEAM : -$68.39M RXRX : -$505.90M

Return for Risk

BEAM vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BEAM

BEAM Risk / Return Rank: 81
BEAM Sharpe Ratio Rank: 82
BEAM Sortino Ratio Rank: 82
BEAM Omega Ratio Rank: 77
BEAM Calmar Ratio Rank: 83
BEAM Martin Ratio Rank: 80

RXRX

RXRX Risk / Return Rank: 20
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 21
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 18
RXRX Martin Ratio Rank: 21

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BEAM vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BEAM	RXRX	Difference
Sharpe ratio: Return per unit of total volatility	1.49	-0.52	+2.01
Sortino ratio: Return per unit of downside risk	2.39	-0.45	+2.84
Omega ratio: Gain probability vs. loss probability	1.27	0.95	+0.31
Calmar ratio: Return relative to maximum drawdown	2.95	-0.63	+3.59
Martin ratio: Return relative to average drawdown	6.34	-1.00	+7.34

BEAM vs. RXRX - Sharpe Ratio Comparison

The current BEAM Sharpe Ratio is 1.49, which is higher than the RXRX Sharpe Ratio of -0.52. The chart below compares the historical Sharpe Ratios of BEAM and RXRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BEAM vs. RXRX - Drawdown Comparison

The maximum BEAM drawdown since its inception was -89.12%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for BEAM and RXRX.

Drawdown Indicators

	BEAM	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-89.12%	-93.13%	+4.01%
Max Drawdown (1Y) Largest decline over 1 year	-38.15%	-58.17%	+20.02%
Max Drawdown (3Y) Largest decline over 3 years	-67.74%	-82.09%	+14.35%
Max Drawdown (5Y) Largest decline over 5 years	-89.12%	-93.13%	+4.01%
Current Drawdown Current decline from peak	-73.41%	-92.31%	+18.90%
Average Drawdown Average peak-to-trough decline	-59.93%	-75.44%	+15.51%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.72%	36.93%	-19.21%

Volatility

BEAM vs. RXRX - Volatility Comparison

The current volatility for Beam Therapeutics Inc. (BEAM) is 23.00%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 25.24%. This indicates that BEAM experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BEAM	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.00%	25.24%	-2.24%
Volatility (6M) Calculated over the trailing 6-month period	53.52%	45.47%	+8.05%
Volatility (1Y) Calculated over the trailing 1-year period	75.50%	71.27%	+4.23%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	76.10%	93.66%	-17.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.82%	93.53%	-12.71%

Dividends

BEAM vs. RXRX - Dividend Comparison

Neither BEAM nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both BEAM and RXRX in my portfolio?

BEAM and RXRX have a correlation of 0.56, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BEAM or RXRX?

RXRX has higher volatility (25.24%) compared to BEAM (23.00%). In terms of maximum drawdown, BEAM dropped -89.12% vs RXRX's -93.13%.

Which has better risk-adjusted returns?

BEAM currently has the higher Sharpe Ratio (1.49 vs -0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.